Table 2 Further in-depth optimization of monophasic deproteinization using different combinations of methanol/ethanol mix and plasma:solvent ratios of 1:3 and 1:9, respectively
From: Technology platform development for targeted plasma metabolites in human heart failure
1:3(Plasma:Solvent) | 1:9(Plasma:Solvent) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Metabolite name | Accesion # | 100% Methanol | 80% Methanol/Ethanol | 50% Methanol/Ethanol | 20% Methanol/Ethanol | 100% Ethanol | 100% Methanol | 80% Methanol/Ethanol | 50% Methanol/Ethanol | 20% Methanol/Ethanol | 100% Ethanol |
Hexanoic acid | HMDB00535 | x | x | x | x | x | x | x | |||
Succinate | HMDB00254 | x | x | x | x | x | x | x | |||
1-Methylhistamine | HMDB00898 | x | |||||||||
Trans −4-Hydrxy-L-proline | HMDB00725 | x | x | x | x | ||||||
Creatine | HMDB00064 | x | x | x | |||||||
L-Malate | HMDB00156 | x | x | x | x | ||||||
Hypoxathine | HMDB00157 | x | x | x | x | x | x | x | |||
a-Ketoglutaric acid | HMDB00208 | ||||||||||
L-lysine | HMDB00182 | ||||||||||
Uric acid | HMDB00289 | ||||||||||
L-Arginine | HMDB00517 | ||||||||||
L-Tyrosine | HMDB00158 | ||||||||||
Indole-3-propionate | HMDB02302 | ||||||||||
Citric acid | HMDB00094 | ||||||||||
Dodecanoic acid | HMDB00638 | x | x | x | x | x | x | x | x | ||
Palmitatic acid | HMDB00220 | x | x | x | x | x | x | x | x | ||
Linoleatic acid | HMDB00673 | x | x | x | x | x | x | ||||
Trans-Vaccenic acid | HMDB03231 | x | x | x | x | x | |||||
Stearic acid | HMDB00827 | x | x | x | x | x | x | x | x | ||
# Targeted Meabolites | 11 | 5 | 11 | 13 | 9 | 8 | 3 | 7 | 1 | 9 | |